A white paper by Tufts Center for the Study of Drug Development, commissioned by Thermo Fisher Scientific, highlights that integrated contract development and manufacturing organization (CDMO) and contract research organization (CRO) platforms can shorten oncology drug clinical trial durations by up to 34 months. The streamlined control over trial phases reduces dormant 'white space,' accelerating decisions and improving operational efficiencies. These findings, presented at the BIO International Convention, suggest a generalizable model for efficient drug development beyond oncology.